Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Schumer Gives Update On Federal Marijuana Legalization And Banking In Meeting With Equity Advocates
https://www.marijuanamoment.net/schumer-gives-update-on-federal-marijuana-legalization-and-banking-in-meeting-with-equity-advocates/?fbclid=IwAR3whwgJ7sohDWBLAAypi9PGrdKtnwbYXrBL3e69WhoLpcMj51dV-vT-tqM
Schumer Gives Update On Federal Marijuana Legalization And Banking In Meeting With Equity Advocates
https://www.marijuanamoment.net/schumer-gives-update-on-federal-marijuana-legalization-and-banking-in-meeting-with-equity-advocates/?fbclid=IwAR3whwgJ7sohDWBLAAypi9PGrdKtnwbYXrBL3e69WhoLpcMj51dV-vT-tqM
I hope it's a good investors day conference. They've made some USA acquisitions that I hope are net cash positive "as is" since USA legalization looks like it's many years off into the future.
BRAINCHIP PODCAST RETURNS WITH CEO SEAN HEHIR
https://brainchipinc.com/brainchip-podcast-ceo-sean-hehir/
First ‘This is our Mission’ podcast of the new year takes listeners on a journey of what to expect from the company in 2022
Laguna Hills, Calif. – January 30, 2022 – BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), a leading provider of ultra-low power high performance artificial intelligence technology and the world’s first commercial producer of neuromorphic AI chips and IP, today announced that its latest “This is our Mission” podcast features an in-depth conversation with recently appointed CEO Sean Hehir. The podcast debuts February 8 at 4 p.m. PST on BrainChip’s website and across popular podcast platforms.
Hehir was named CEO this past November and is tasked with guiding the company towards full commercialization of BrainChip’s Akida™ neuromorphic computing platforms. The conversation between him and host Rob Telson, BrainChip Vice President of Worldwide Sales, highlights Hehir’s track record of organizational development, strategic alliances, and go-to-market programs which have driven revenue growth for large technology organizations, including HP, Compaq, and Fusion-io. The two also delve into BrainChip’s next growth phase and how the company expects its leading AI technology to impact cutting-edge markets like automotive, transportation, consumer, aerospace, medical and industrial IoT.
“Nothing like interviewing your new boss to start the new year,” said Telson. “It is a great conversation to help our audience get to know Sean, his background and his vision for the company. Having a platform like our monthly podcast allows us the opportunity to speak directly to those in the technology community, investors and partners and share information about where we stand and where we’re headed. It is great to get back to our normal podcast routine with such a positive and affirmative conversation about how Akida continues to revolutionize markets with its Edge AI capabilities.”
BrainChip deploys AI at the edge in a way that existing technologies cannot. The company’s tech is both high-performance and ultra-low power, enabling a range of capabilities including on-chip, in-device one-shot learning. BrainChip’s IP can be used in a wide range of applications from industrial IoT, cybersecurity, and autonomous vehicles to smart sensors that can detect and act on visual features, odors, taste, touch, and sound.
The BrainChip Podcast is a monthly event intended to provide company and industry insight for the engineering community in target markets, as well as analysts, technical and financial press and investors. Past podcast episodes are available to listen to at https://brainchipinc.com/brainchip-podcasts/
About BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY) BrainChip is a global technology company that is producing a ground-breaking neuromorphic processor that brings artificial intelligence to the edge in a way that is beyond the capabilities of other products. The chip is high performance, small, ultra-low power and enables a wide array of edge capabilities that include on-chip training, learning and inference. The event-based neural network processor is inspired by the spiking nature of the human brain and is implemented in an industry standard digital process. By mimicking brain processing BrainChip has pioneered a processing architecture, called Akida™, which is both scalable and flexible to address the requirements in edge devices. At the edge, sensor inputs are analyzed at the point of acquisition rather than through transmission via the cloud to a data center. Akida is designed to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications. The reduction in system latency provides faster response and a more power efficient system that can reduce the large carbon footprint of data centers.
Additional information is available at https://www.brainchipinc.com
Follow BrainChip on Twitter: https://www.twitter.com/BrainChip_inc
Follow BrainChip on LinkedIn: https://www.linkedin.com/company/7792006
FIRE & FLOWER AMENDS STRATEGIC LICENSING PARTNERSHIP AND OPTION TO ACQUIRE FIRE & FLOWER HOLDINGS US (FORMERLY AMERICAN ACRES)
JANUARY, 31, 2022
A CVS article to make you smile CVS: Growing With Larger Healthcare Market And Telehealth
Jan. 28, 2022 9:46 AM ET
https://seekingalpha.com/article/4482444-cvs-growing-larger-healthcare-market-telehealth-stock-buy?mailingid=26518489&messageid=2800&serial=26518489.4944&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=26518489.4944
Summary
* CVS is undervalued based on current S&P ratios.
* CVS has plenty of growth ahead.
* CVS has an interesting partnership with Teladoc that gets it access to a nice, growing segment of the healthcare market.
Since I last covered CVS (NYSE:CVS), anyone sharing in my advice would have seen gains of 80% or more. This "value" name has had great growth over the last year or so - and I believe they still have many opportunities ahead. However, it seemed important to choose if it was still worth the buy rating for anyone who is newer to the CVS name.
CVS is no longer the once boring corner drugstore as it has officially moved into the larger healthcare market. It leveraged itself to healthcare - in a move many did not like - when it purchased Aetna years ago for $69 Billion. Loaded with debt, but having plenty of income, the company was ignored by investors until rather recently when the market started noticing that it was executing its strategy… and doing it well.
The debt burden has mostly been managed as CVS has paid down $21 Billion and reached its stated goal, a leverage ratio under 3x, roughly a year early. (The dividend was halted at $0.50 per share per quarter for the entire time to assist in paying down the debt quicker. It has since had an announced 10% dividend increase, likely the first of many such yearly announcements.) Stock pickers moved on and missed the opportunity of a company with powerful earnings, including missing the growing healthcare company it was creating. Value investors who saw earnings knew that if CVS would stick to the plan, things could work out and many holders have made out well with gains of 50-100% over mere years. (Not bad at all for a "value stock.") CVS is still a value-priced company, but does it have enough growth ahead?
The Basic Business Model
CVS has created a growing, near-whole healthcare company. CVS's Caremark division provides roughly one-third of company revenues while working behind the scenes with health insurers as a pharmacy. (Technically a Pharmacy Benefit Manager, or PBM.) They are using the 'boring drugstore' PBM by leveraging what is the nation's largest pharmacy service - more technically the highest prescription drug market - to deliver medicines to anyone and everyone who will use the service.
With the purchase of Aetna, CVS gained access to health benefits and managed care for over 23 million members, which made them the third-largest health insurer in the U.S. This is a competitive market, and Anthem (NYSE:ANTM) and UnitedHealth (NYSE:UNH) have a rather large lead, but continually adding services and more convenient access centers should assist CVS in growing this business.
Then Aetna President, Karen Lynch, became the President and CEO of CVS last year. With her Aetna background, she rightfully seems highly focused on increasing income via healthcare coverage and offerings. The previous President, Mr. Merlo, and the board even adjusted the name from CVS/Caremark to CVS Health, further showing what they are focused on.
This is really the reason for CVS "Minute Clinics" and "HealthHubs". CVS is pushing more and more services into 'the corner drugstore' and revamping layouts to create treatment centers for simpler-yet-common chronic diseases, like sleep apnea or diabetes, as well as pushing into mental and behavioral health. Pairing with Teladoc (TDOC) and using its services for virtual visits, CVS is leveraging their technology to be even more convenient to consumers all over.
The Amazon Threat
Amazon (AMZN) is attacking the healthcare market leveraging its massive online presence and distribution warehouses in strategic areas. Focusing on quick shipping to most locations, Amazon has become a get anything-and-everything online shop with great brand awareness. Amazon sees the growth in the healthcare and prescription markets and has been trying to enter and gain share since its 2018 acquisition of PillPack, but consumers still need a doctor and prescription to use this service.
Amazon, Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) and JPMorgan all paired together to tackle the healthcare cost issue, creating a service known as Haven, and came up lacking - with all eventually cancelling this venture. Amazon still sees dollar signs and is undeterred from the healthcare market and is now launching - or maybe you could say rebranding as - AmazonCare in order to assist folks in getting a doctor visit and prescription online. I don't deny that any entrance by Amazon is significant; however, they have a tough haul trying to gain employers and consumers one at a time. CVS already has many of these employer and consumer relationships. But Prime members could possibly be swayed by the Amazon effect.
Not to be left out, Walmart (WMT) purchased MeMD and has benefitted from its store pharmacies to bring more things to more customers. The big retail stores are not as numerous as CVS, however, they do have half the reach and are doing everything they can to make their stores a one-stop-shop. The larger store focus does create other challenges, but Walmart has faced challenges before.
CVS's Angle of Attack
CVS is attacking the same overall healthcare market, a massive and growing Total Addressable Market (TAM), but from a different angle as the above companies. It is also using different tactics from the larger medical insurance companies, UnitedHealth and Anthem, as it looks for more market share - and profits. As mentioned in previous articles here and here, CVS is leveraging its 9,900 stores and distribution centers to get closer to people. Stats show that roughly 80% of all U.S. citizens are less than 10 miles from a CVS store. This gives CVS a unique proximity to consumers, a convenience factor if you will, as their ubiquitous "corner stores" reach into nearly every city.
CVS stores, roughly 1,500 by end of 2021, are being set up as HealthHubs. HealthHubs are almost like urgent care clinics inside the existing store location, giving folks access to convenient and lower cost after-hours, or just simpler, health visits. On top of this, stores are being set up to ship products that are ordered online, with many also as convenient UPS drop-off locations making each location a mini distribution center. The digital push makes this smaller store, networked distribution increasingly easier.
True, CVS has announced their intention to close some stores, roughly 900 over the next three years. This still leaves 9,000 stores across the Nation - and the savings not spent on physical location rent as well as some staffing - to improve and add more services as they rework other store offerings. They have stated numerous times that they are optimizing their "retail portfolio to serve as community health destinations." They are doing this by building, or enhancing, more stores into HealthHub locations. As they expand care center services, they are working with technology to continue expanding their reach and expertise by reaching people digitally, and this is where the picture gets even better…
CVS's Digital Strategy
CVS already states they have 35 million digital customers. Most of these are folks who are using the CVS app to order products and prescriptions from CVS. Increasingly I would imagine the app and digital service will become a way to reach doctors for questions and telehealth visits as CVS pushes towards virtual visits. (Aside from offering coupons to keep users more sticky.)
CVS is leveraging their drugstore/PBM's highest prescription drug market (again, a roughly 25% market share) and the national healthcare reach of Aetna to reach more and more consumers with convenient access to health services. On top of this CVS is partnering with Teladoc, providing opportunity and even more reach to consumers who are looking for virtual doctor visits and convenience.
Some Numbers
Previous earnings came out in November of 2021, so we are anxiously looking forward to the next statement on February 9th, 2022. Their prior Q3 announcements showed beat on pretty much all fronts, including an over $3 Billion top-line beat. Non-GAAP EPS of $1.97 beat expectations by $0.18. (GAAP EPS had an EPS of $1.20, a rare miss of $0.20) This all was from a healthy revenue or $73.79 Billion, a roughly 10% Year over Year gain.
FCF for the quarter was $4.9 Billion, up from $1.3 Billion in the same quarter of 2020. Adjusted earnings for the full year, which they will announce soon, were expected to be roughly 6% growth. This increasing income allowed CVS to pay down $6.5 Billion in long-term debt year-to-date and get roughly $21 Billion off the books from the transformational Aetna merger from 2018. Management had previously estimated to hit a target leverage ratio of about 3x at the end of 2022. They hit that number roughly a year early.
Comparisons in and Outside of the Industry
CVS is really a company looking to be unique by offering a host of products that nobody else offers. While they are unlikely to be the only company offering these services, they are moving to transform the industry by leveraging their strengths in a logical manner. They have the opportunity to truly differentiate themselves from others, depending on what they do from here. Either way, they surprised many market enthusiasts and analyst "experts" by doing what they said they would when they purchased Aetna years ago.
Walgreens (WBA) is really the closest similar business, though they do not have the large healthcare offerings. Walgreens seems to be pivoting to a similar mold as CVS and has some good prospects going forward, possibly also being undervalued, but that is a different discussion altogether. In the comparisons below, I included Amazon - which is looking to compete - as well as Walmart and a few others that have similar income or some overlapping business.
https://static.seekingalpha.com/uploads/2022/1/27/877449-16432634714064581_origin.jpg
Ratios and Comparison List, Self-Created using current Seeking Alpha data
This stock list shows that even with the gains over the last year or so, CVS still does not get all the market credit it deserves. Target (NYSE:TGT) has a somewhat similar market-cap but roughly one-third the revenue or CVS. UnitedHealth is in a similar field but is valued over 40% higher even with a lower dividend yield. Numerous other comparisons are rather easy to see.
"Strategic Cash Investments"
Ok, admittedly this section is where I get into the weeds a bit. CVS has straightforward plans and can improve results with simple execution of their strategy, but a few things were mentioned many times that have me wondering. In the last presentation at the J.P. Morgan Healthcare Conference, CVS stated their plan for long-term capital was both very simple to understand and attractive to long-term investors. Goals include making sure they have "differentiated care delivery assets" including virtual assets and a "deep health care experience". They also look to scale assets and to use a connected and digital model including "virtual and in-home care".
https://static.seekingalpha.com/uploads/2022/1/27/877449-1643263546569345_origin.jpg
https://static.seekingalpha.com/uploads/2022/1/27/877449-16432637053556082_origin.jpg
CVS later states that they want to:
* Invest 25% to 35% into the business to grow and capture more opportunities.
* Allow for 45% to 55% for "value-added" or "capability-focused M&A" opportunities.
* Provide an attractive dividend with roughly 20%, growing over time with EPS gains.
What has me so interested is their constant mentions of the words 'virtual' and 'digital-first' in all the most recent materials.
https://static.seekingalpha.com/uploads/2022/1/27/877449-16432637975863855_origin.jpg
J.P. Morgan Health Conference Slide 7 for CVS, Author Highlights point 3 and 4
It seems to simply show that CVS is going to continue to use Teladoc's suite of services to continue to grow and diversify. It might be rampant speculation, though something I would highly consider if I was in their position to continue to leverage the relationship with Teladoc to offer more virtual care. (This would allow CVS to reduce the store count, the 900 expected reduction over the next three years, without really losing the consumers in those regions and still offering patient services.)
If I am allowed to be even more bold, I would assert that CVS could even consider purchasing Teladoc for its assets and growth. (Teladoc purchased/merged with Livongo in October of 2020 in an all-stock deal. Admittedly, the deal was priced at a combined company value of $18.5 Billion. Current valuation shows the Teladoc merger has a lot of naysayers as it has a current market cap of $12 Billion right as it nears profitability. This could be worth it at the right price, likely only costing CVS one year's FCF.)
Another interesting thought is that the global telehealth market is forecasted to grow anywhere from $300 Billion to $700 Billion by 2028. (That is outstanding growth opportunity even on the smaller side!) CVS Health and Aetna, using Teladoc software, could have some early signs of software acceptance. The access to Teladoc software could show CVS some of the income that Teladoc is expecting, but also might make a bit easier as they share access. Admittedly, the roughly 25-30% compound growth TDOC expects would assist CVS in beating the numbers if it were under the CVS Health umbrella. (But I digress...)
Wrapping Things Up
Speculation aside, CVS - the once stodgy corner drugstore - is finally starting to catch the attention of the market. It has transformed itself into a national player on the healthcare stage and is setting itself up for more growth, while still being a great value. Of course, current market dynamics are likely to be very rocky as inflation and Fed bonds, rates, etc. take center stage.
If I had no CVS stock today, I would consider this a moderate Buy. CVS is undervalued when compared to most of the market. (S&P current ratio shows a PE of 24 while CVS gets a PE ratio of only 12.) Since I currently own CVS and have enjoyed the nice gains over the last year or so, I am in no hurry to add shares at this point. However, I will heavily consider it if it falls in a larger market correction and I would recommend others consider the same.
Disclosure: I/we have a beneficial long position in the shares of CVS, TDOC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
This prospectus supplement relates to the offer and resale by the selling stockholders identified in this prospectus supplement of up to an aggregate of 5,651,061 Subordinate Voting Shares (the “Subordinate Voting Shares”). We will not receive any of the proceeds from the sale of our Subordinate Voting Shares by the selling stockholders.
The selling stockholders identified in this prospectus supplement may offer our Subordinate Voting Shares from time to time through public or private transactions. The Subordinate Voting Shares offered by the selling stockholders may be sold at market prices prevailing at the time of sale, at prices related to such market prices, at a fixed price or prices subject to change, or at negotiated prices. See “Plan of Distribution.”
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001795139/78927682-2fa9-44ff-b684-4bccfbef40f9.pdf
Copies of the Succession Agreements are filed as Exhibits 4.1, 4.2 and 4.3 with this Current Report on Form 8-K and are incorporated herein by reference.
Item 8.01 Other Events.
https://ir.tilray.com/node/10271/html
On January 27, 2022, Tilray Brands, Inc. (the “Company”), and Glas Trust Company LLC (“Glas Trust”) entered into Agreements of Resignation, Appointment and Acceptance (the “Succession Agreements”) with Computershare Trust Company, N.A. (“Computershare”). Pursuant to the Succession Agreements, Computershare will replace Glas Trust as trustee under each of the following indentures (collectively, the “Indentures”) with respect the Company’s debt securities issued or to be issued under the Indentures: (i) Indenture dated as of August 23, 2019 (as supplemented, amended, or modified on each of November 13, 2019, and November 22, 2019) by and between the Company and Glas Trust; (ii) Indenture dated as of October 10, 2018 by and between the Company and Glas Trust; and (iii) Indenture dated as of April 23, 2019 (as supplemented on April 30, 2019) by and between the Company and Glas Trust .
Cresco Labs Announces Launch of Khalifa Kush Products at Cookies Dispensaries Throughout California
https://investors.crescolabs.com/investors/press-releases/press-release-details/2022/Cresco-Labs-Announces-Launch-of-Khalifa-Kush-Products-at-Cookies-Dispensaries-Throughout-California/default.aspx
January 28, 2022
Wiz Khalifa’s bestselling cannabis brand expanded to California through an exclusive cultivation & product collaboration with the Company’s FloraCal Farms and Continuum platform
CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced flower and pre-rolls from Khalifa Kush are available for sale at Cookies stores throughout California. Cresco Labs has an exclusive cultivation and product collaboration agreement with multi-platinum-selling, GRAMMY® and Golden Globe® Award-nominated recording artist Wiz Khalifa’s cannabis brand. Through the partnership, the Company’s FloraCal Farms and Continuum distribution platform will be the sole producer and distributor, respectively, of premium branded products featuring Khalifa Kush’s signature “KK” strain in California. An expanded line is expected to arrive at additional retail partners throughout the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220128005052/en/
Through a cultivation & product collaboration partnership with Cresco Labs’ FloraCal Farms and Continuum, flower and pre-rolls from Khalifa Kush are now for sale at Cookies stores throughout California. (Photo: Business Wire)
Through a cultivation & product collaboration partnership with Cresco Labs’ FloraCal Farms and Continuum, flower and pre-rolls from Khalifa Kush are now for sale at Cookies stores throughout California. (Photo: Business Wire)
“Wiz Khalifa has been a longtime advocate for cannabis legalization, with a namesake OG strain beloved by many in other states. Today, we’re thrilled to bring his brand to cannabis lovers and his fans in California,” said David Gacom, West Region Regional President at Cresco Labs. “We’re focused on bringing a curated portfolio of leading brands to California retailers, and Khalifa Kush is a natural addition with its focus on delivering top quality cannabis. We’re excited to work with the talented Khalifa Kush team to grow its cannabis and commercialize its products.”
"We're excited to launch Khalifa Kush in California with Cresco Labs; we've been working for years on this project." said Wiz Khalifa. "The KK grown at FloraCal is the best I've smoked, and I’m excited for the people of California to enjoy the original KK."
“FloraCal Farms and Continuum, with their best-in-class cultivation capabilities and significant scale and penetration, have proven to be the premier cultivator and distribution platform in the largest and most competitive market in the country, and we’re honored to partner with their teams to expand Khalifa Kush’s footprint in California,” said DJ Saul, CEO of Khalifa Kush.
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com. Follow Cresco Labs on Facebook, Instagram, Twitter and LinkedIn.
About Khalifa Kush
Khalifa Kush products were first commercialized in the U.S. in 2015 by global icon Wiz Khalifa. The company has achieved continued growth and success by focusing on high quality and highly sought-after products in legalized cannabis markets. The Khalifa Kush brand offers a growing lineup of flower, pre-rolls, vapes, edibles, and concentrates, powered by proprietary genetics, in partnership with Compound Genetics. Khalifa Kush is available in select markets including Nevada, Arizona and Utah. Learn more about the upcoming California launch, Michigan launch and shop apparel at KHALIFAKUSH.COM.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220128005052/en/
Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
Investors:
investors@crescolabs.com
Khalifa Kush / Wiz Khalifa press:
Dvora Englefield Dvora.Englefield@ledecompany.com
Courtni Asbury Courtni.Asbury@ledecompany.com
Chris Iacullo Chris.Iacullo@ledecompany.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
Source: Cresco Labs
Debt rising to $425M--->>>Trulieve Announces Closing of $75 Million Private Placement of 8% Senior Secured Notes
January 28, 2022 at 8:39 AM EST
Investor Presentation Q1 2022
https://www.indiva.com/investors/presentation/
Indiva to Hold Investor Webinar, Feb. 8
January 26, 2022 1:34 PM EST
https://www.streetinsider.com/Newsfile/Indiva+to+Hold+Investor+Webinar%2C+Feb.+8/19508575.html
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2022) -
Stocks2Watch would like to invite the Investment Community to Indiva's Investor Webinar, Tuesday, February 8 at 1pm (PT) 4pm (ET).
Individual investors, institutional investors, advisors, and analysts are invited to register now to attend the presentation.
REGISTER NOW AT: https://app.livestorm.co/stocks2watch/explore-indiva-in-2022
Niel Marotta, President & CEO, will provide an Indiva investor update at 1pm pacific standard time on Tuesday, February 8 and will discuss everything within the world powered by INDIVA. This live presentation will last approximately 20 minutes and then we'll transition into an interactive Q & A session.
It was a banner year for Indiva in 2021, and they have no intention of slowing down. In 2022, they'll be launching Jewels, chewable cannabis tablets made from dried fruit and cannabis sugar - these game-changing edibles will be available in two flavours: Raspberry 1:1 and Strawberry.
INDIVA is also set to launch Wana Quick Midnight Berry, a new sleep gummy from the award-winning Wana brand featuring a custom indica blend of CBN, CBD, and THC.
2022 will also see the launch of Grön products in Canada (pronounced "grewn"). Grön is a women-led and women-owned edible company based in Portland, Oregon.
Indiva recently partnered with Grön to bring Canadians their innovative edibles portfolio, which includes candy-coated chocolate 'Pips', chocolate bars, gelatin gummy 'Pearls', and other novel edible products. Production will start on Grön products as soon as possible, with deliveries expected to begin in late Q2/early Q3 2022.
REGISTER NOW AT: https://app.livestorm.co/stocks2watch/explore-indiva-in-2022
Registration Open to Investors and Finance Professionals >>> This event is suitable for private investors, brokers, fund managers, financial institutions, funds, buy & sell side analysts, influencers, newsletter writers and journalists. The event is not suitable for people pursuing commercial opportunities.
ABOUT INDIVA (TSXV: NDVA) (OTCQX: NDVAF)
Indiva sets the standard for quality and innovation in cannabis. As a Canadian licensed producer, Indiva produces and distributes award-winning cannabis products nationally, including Bhang® Chocolate, Wana" Sour Gummies, Slow Ride Bakery Cookies, Grön Products, Jewels Chewable Tablets, Ruby® Cannabis Sugar, Sapphire" Cannabis Salt, as well as capsules, pre-rolls and premium flower under the INDIVA and Artisan Batch brands.
ABOUT STOCKS2WATCH
Stocks2Watch hosts Virtual Investor Luncheons and Online Presentations for Publicly Listed and Pre-Public Companies. To learn more about Stocks2Watch and view a complete list of events, please visit www.stocks2watch.ca.
CONTACT:
Neil Lock,
info@stocks2watch.ca
604-410-4888
Corporate Logo
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111772
Cresco Labs Expands Sunnyside in Florida’s Gulf Coast With New Clearwater Dispensary
https://investors.crescolabs.com/investors/press-releases/press-release-details/2022/Cresco-Labs-Expands-Sunnyside-in-Floridas-Gulf-Coast-With-New-Clearwater-Dispensary/default.aspx
January 27, 2022
(WTF see red.) Trulieve Exclusively Brings Miami Mango Cannabis to South Florida Market
January 27, 2022 at 7:35 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-exclusively-brings-miami-mango-cannabis-south-florida
Regionally renowned Mango Haze strain will be available to Trulieve patients year-round
TALLAHASSEE, Fla., Jan. 27, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced a partnership with South Florida-based cannabis company, Miami Mango. The brand's popular Mango Haze will be the first strain launched exclusively to Trulieve medical patients in the South Florida market.
"It's incredible to be able to offer Miami Mango in my hometown of Boynton Beach and the region through Trulieve, the market leader in Florida," said Alex Villegas aka Miami Mango, CEO of Miami Mango. "I know that our shared commitment to quality cannabis products and patient care will benefit both long-time fans and those new to the Miami Mango family."
Beginning in late February, Trulieve will offer Miami Mango's Mango Haze in a flight to include flower, pre-rolls, oils, and concentrates.
"Trulieve is excited to partner with Miami Mango, which has been sought out in South Florida and beyond for decades," said Kim Rivers, CEO of Trulieve.
Aleafia (in blue below) is using new means to distribute product--->>> FIRE & FLOWER LAUNCHES E-COMMERCE DISPENSARIES FOR CANADIAN LICENSED PRODUCERS' BRANDS
JANUARY, 27, 2022
https://investors.fireandflower.com/news/news-details/2022/Fire--Flower-Launches-E-Commerce-Dispensaries-for-Canadian-Licensed-Producers-Brands/default.aspx
New e-commerce offering from Hifyre and Fire & Flower will equip brands with a direct-to-consumer sales platform enabled by delivery and a 100+ store retail network
TORONTO, Jan. 27, 2022 /CNW/ - Fire & Flower Holdings Corp. ("Fire & Flower'', or the "Company") (TSX: FAF) (OTCQX: FFLWF), a leading, technology-powered, cannabis retailer, today announced the expansion of the Company's e-commerce offering with the launch of online branded dispensaries that will enable direct-to-consumer sales using drop shipping for leading licensed producers ("LPs").
The expanded e-commerce capabilities continues the buildout of Fire & Flower's proprietary technology stack that is focused on delivering a seamless digital consumer experience including in-store fulfillment and delivery. The new virtual retail platforms, powered by the Company's proprietary data and analytics platform, Hifyre, allow for cannabis consumers to shop LP-branded online marketplaces for direct-to-consumer sales.
Consumers can shop for their favorite brands' cannabis products and have those orders completed through in-store fulfillment at one of Fire & Flower's 100+ retail locations or via delivery (where permitted) through its recently acquired delivery subsidiary, Pineapple Express Delivery.
Initial brands available for purchase through Fire & Flower's platforms include Auxly, Aleafia, Cronos Group, FIGR and Wagners. The e-commerce marketplaces will also generate digital advertising revenue through the Hifyre Reach platform which connects brands to intending consumers, and provides a path to measure purchasing behavior both in-store and online.
"Retail is continuously evolving and we found that a growing segment of our customer base is looking for a seamless digital solution that allows them to connect and shop directly from their favorite brands. We are uniquely positioned to meet that demand by providing a streamlined retail experience to customers across North America through our scalable, digital solution, powered by our Hifyre technology platform. Through the creation of branded dispensaries we are delivering additional value to LPs by enabling greater customer acquisition through a top-of-funnel virtual platform that can also fulfill those direct orders either in person or via delivery," said Trevor Fencott, Chief Executive Officer of Fire & Flower.
"Not only does the creation of these online platforms support the expansion of our Spark Perks membership program and empower our entire technology platform with increasing sources of consumer buying preferences, it creates an opportunity to generate new digital advertising revenue streams through our Hifyre Reach platform," concluded Fencott.
"We're excited to engage directly with consumers through Fire & Flower's advanced consumer technology," said Andrew MacMillan, SVP Commercial, Auxly. "To successfully compete in today's competitive cannabis market, it is essential to understand purchase habits and preferences. Through our newly branded e-commerce dispensaries, not only can we track consumer activity right through to purchase and conversion, but most importantly, we are also delivering an enhanced experience of our brands. This direct-to-consumer online model will drive new opportunities to more effectively serve our expanding customer base and support our sales growth."
About Fire & Flower
Fire & Flower is a leading, technology-powered, adult-use cannabis retailer with over 100 corporate-owned stores in its network. The Company leverages its wholly-owned technology development subsidiary, Hifyre Inc., to continually advance its proprietary retail operations model while also providing additional independent high-margin revenue streams. Fire & Flower guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the Hifyre™ digital retail and analytics platform empowers retailers to optimize their connections with consumers. The Company's leadership team combines extensive experience in the technology, cannabis and retail industries.
Through the strategic investment of Alimentation Couche-Tard Inc. (owner of Circle K convenience stores), the Company has set its sights on global expansion as new cannabis markets emerge and is poised to expand into the United States when permitted through its strategic licensing agreement with Fire & Flower U.S. Holdings upon the occurrence of certain changes to the cannabis regulatory regime.
Fire & Flower is a multi-banner cannabis retail operator that owns and operates the Fire & Flower, Friendly Stranger, Happy Dayz and Hotbox brands. Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc. and Friendly Stranger Holdings Corp., licensed cannabis retailers that own and operate cannabis retail stores in the provinces of Alberta, Saskatchewan, Manitoba, British Columbia and Ontario, and the Yukon territory.
To learn more about Fire & Flower, visit www.fireandflower.com.
About Hifyre
The Hifyre Digital Retail and Analytics Platform is a proprietary ecosystem of products that includes the Spark Perks member program, Hifyre ONE retail software platform, Hifyre IQ cannabis data and analytics platform, and Hifyre Reach digital advertising network.
The Hifyre platform also supports Fire & Flower's advanced operations and provides a competitive advantage in providing a tailored digital experience and understanding consumer behaviours in the evolving cannabis market.
To learn more about Hifyre, visit www.hifyre.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions.
Forward-looking statements are based on the opinions and estimates of management of Fire & Flower at the date the statements are made based on information then available to the Fire & Flower. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements, including market conditions and the business of the Company. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Fire & Flower, which may cause Fire & Flower's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include: regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the impact of the COVID-19 pandemic; the ability of the Company to successfully achieve its business objectives and political and social uncertainties.
No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated April 30, 2021 and the heading "Risks and Uncertainties" in the management discussion and analysis for the quarter ended October 30, 2021 filed on its issuer profile on SEDAR at www.sedar.com. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
SOURCE Fire & Flower Holdings Corp.
Unilever to Cut 15% of Senior Managers as Peltz Adds Pressure
Thomas Buckley
Tue, January 25, 2022, 6:32 AM·2 min read
https://finance.yahoo.com/news/unilever-cull-15-senior-managers-093148786.html
Unilever to Cut 15% of Senior Managers as Peltz Adds Pressure
(Bloomberg) -- Unilever Plc plans to cut 15% of its senior managerial positions to speed decision-making as activist investor Nelson Peltz puts more pressure on the consumer-goods giant.
Alan Jope is making his biggest job cuts since becoming chief executive officer three years ago, eliminating about 1,500 positions as Unilever also reduces junior-management staff by 5%. The company is making ice cream, beauty and personal care independent units as it reorganizes its businesses into five groups. Last week, Unilever said it planned to announce the reorganization.
The shares traded 0.9% lower at 11:25 a.m. in London. Bloomberg earlier reported the company planned to reduce staff.
Jope is at a crucial juncture, coming under increasing pressure to chart a new course as the company’s share price lags rivals.
“We are still not hearing what we want,” Royal Bank of Canada analysts led by James Edwardes Jones wrote. “The new operating model announced today might make divestments easier, but we would prefer them to focus on reinvesting cost savings behind their brands and categories. There’s also no signs of any culture change yet given all new segment heads are Unilever incumbents.”
Among the departing senior managers is Sunny Jain, a former Amazon.com Inc. executive who replaced Jope as president of Unilever’s beauty and personal-care arm in 2019. That business, which has been growing at the slowest pace of Unilever’s three major divisions, is being broken up into two under the new organization.
Unilever’s decision to also separate its Foods and Refreshments business into two separate entities will bring more transparency to the performance of its ice-cream operations, which includes brands such as Ben & Jerry’s, Klondike and Magnum and has been speculated by some analysts as a potential disposal target.
Jope is seeking to reorganize the foods business around healthier habits, aiming to build a portfolio of plant-based meat and dairy alternative brands that will generate 1 billion euros worth of revenue by 2025. He also has expanded in the fast-growing vitamins, minerals and supplements space with the acquisition of Olly Nutrition in 2019.
Unilever last week abandoned its pursuit of GlaxoSmithKline Plc’s consumer-health business after the drugmaker rejected its overtures and investors disparaged the offer. Fund manager Terry Smith called the bid a “near-death experience.” Only days earlier, he had urged Unilever to focus more on fixing its own business than seeking to promote the sustainability ethos of brands such as Hellmann’s mayonnaise.
The company employs about 150,000 people globally.
Peltz’s Trian Fund Management has amassed a holding in Unilever over the past few months, people familiar with the situation said earlier this week. The exact size and Peltz’s intentions couldn’t be immediately learned.
Kinder Morgan to Hold 2022 Investor Day
01/24/2022
HOUSTON--(BUSINESS WIRE)-- Representatives of Kinder Morgan, Inc. (KMI) intend to make presentations in Houston, Texas on January 26, 2022 at the Kinder Morgan 2022 Investor Day regarding the results for fiscal year 2021, the near-term outlook for 2022, as well as the long-term outlook for KMI.
Interested parties will be able to view the materials to be presented at the event by visiting KMI’s website at: https://ir.kindermorgan.com/events-and-presentations/default.aspx. The presentations will also be accessible by audio webcast (both live and on-demand) on KMI’s website at the same web address. Live presentations are scheduled to begin at 8 a.m. CT, and an archived webcast will remain available for at least 90 days on KMI’s website at the above address.
About Kinder Morgan
Kinder Morgan, Inc. (NYSE: KMI) is one of the largest energy infrastructure companies in North America. Access to reliable, affordable energy is a critical component for improving lives around the world. We are committed to providing energy transportation and storage services in a safe, efficient, and environmentally responsible manner for the benefit of people, communities and businesses we serve. We own an interest in or operate approximately 83,000 miles of pipelines, 143 terminals and 700 billion cubic feet of working natural gas storage capacity. Our pipelines transport natural gas, renewable fuels, refined petroleum products, crude oil, condensate, CO2 and other products, and our terminals store and handle various commodities including gasoline, diesel fuel, chemicals, ethanol, metals and petroleum coke. Learn more about our renewables initiatives on the low carbon solutions page at www.kindermorgan.com.
Media Relations
newsroom@kindermorgan.com
Investor Relations
(800) 348-7320
km_ir@kindermorgan.com
Source: Kinder Morgan, Inc.
MedMen Promotes Tyson Rossi to Chief Strategy Officer
01/25/2022
https://investors.medmen.com/press-releases/press-release-details/2022/MedMen-Promotes-Tyson-Rossi-to-Chief-Strategy-Officer/default.aspx
LOS ANGELES--(BUSINESS WIRE)-- MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a leading cannabis retailer with operations across the nation, today announced the appointment of Tyson Rossi to the role of Chief Strategy Officer.
Rossi has been a member of MedMen’s executive management team since 2019, most recently serving as Senior Vice President, Product and Revenue. He is a retail and cannabis industry veteran, with over 25 years of experience in global brand strategy and vertical cannabis operations, including over a decade of experience in the legal cannabis space. Rossi co-founded a number of cannabis ventures, including Arizona-based multistate craft edibles company Flourish Cannabis; Bodee Holdings, Inc., a privately held cannabis company headquartered in Phoenix, Arizona; and Los Angeles-based Edible Solutions, a leading consulting agency in the cannabis industry.
“We’re thrilled to promote Tyson Rossi to the role of Chief Strategy Officer, responsible for driving MedMen’s company strategy and expansion efforts while overseeing all product-related activities of our business. During his time at MedMen, Tyson’s keen retail insights and deep understanding of both product and the global cannabis landscape have been invaluable to the success of our business and the continued evolution of the MedMen brand,” said Michael Serruya, Interim CEO, MedMen. “I have the utmost confidence in Tyson’s ability to lead strategy as MedMen advances into a new phase of growth and progress, prioritizing profitability, a diverse roster of best-in-class brands, and the continued refinement of the industry’s premier retail experience.”
ABOUT MEDMEN:
MedMen is North America’s leading cannabis retailer with flagship locations in Los Angeles, Las Vegas, Chicago, and New York. MedMen offers a robust selection of high-quality products, including MedMen-owned brands [statemade], LuxLite, and MedMen Red through its premium retail stores, proprietary delivery service, as well as curbside and in-store pickup. MedMen Buds, an industry-first loyalty program, provides exclusive access to promotions, product drops and content. MedMen believes that a world where cannabis is legal and regulated is safer, healthier and happier. Learn more about MedMen and The MedMen Foundation at www.medmen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005344/en/
MedMen Media Contact:
Lisa Weser
MedMen@Trailblaze.co
MedMen Investor Relations Contact:
Investors@MedMen.com
Source: MedMen Enterprises Inc.
View all news
Green Thumb Industries to Hold Fourth Quarter and Full Year 2021 Earnings Conference Call on March 1, 2022
JANUARY 25, 2022
https://investors.gtigrows.com/investors/news-and-events/press-releases/press-release-details/2022/Green-Thumb-Industries-to-Hold-Fourth-Quarter-and-Full-Year-2021-Earnings-Conference-Call-on-March-1-2022/default.aspx
CHICAGO and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RYTHM, Dogwalkers and incredibles branded cannabis products, today announced it will hold a conference call on Tuesday, March 1, 2022, at 8:00 a.m. ET following the release of its fourth quarter and full year 2021 financial results.
The earnings conference call may be accessed by dialing 844-883-3895 (Toll-Free) or 412-317-5797 (International) with conference ID: 10163013. Investors may pre-register for the call by navigating to https://dpregister.com/sreg/10163013/f0aaebb97c. A live audio webcast of the call will also be available on the Investor Relations section of Green Thumb’s website at https://investors.gtigrows.com and will be archived for replay.
About Green Thumb Industries
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. The company also owns and operates rapidly growing national retail cannabis stores called Rise. Headquartered in Chicago, Illinois, Green Thumb has 17 manufacturing facilities, 73 open retail locations and operations across 15 U.S. markets. Established in 2014, Green Thumb employs approximately 3,800 people and serves millions of patients and customers each year. The company was named to Crain’s Fast 50 list in 2021 and a Best Workplace by MG Retailer magazine in 2018, 2019 and 2021. More information is available at www.GTIgrows.com.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements that we believe are, or may be considered to be, “forward-looking statements.” All statements other than statements of historical fact included in this document regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as “may,” “will,” “expect,” “intend,” “estimate,” “foresee,” “project,” “anticipate,” “believe,” “plan,” “forecast,” “continue,” “suggests” or “could” or the negative of these terms or variations of them or similar terms. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. Further information on these and other potential risks that could affect the Company’s business and financial condition and the results of operations are included in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and elsewhere in the Company’s filings with the SEC, which are available on the SEC’s website, at www.sedar.com or at https://investors.gtigrows.com. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this document, which reflect management’s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements.
FIRE & FLOWER COMPLETES ACQUISITION OF PINEAPPLE EXPRESS DELIVERY
JANUARY, 25, 2022
https://investors.fireandflower.com/news/news-details/2022/FIRE--FLOWER-COMPLETES-ACQUISITION-OF-PINEAPPLE-EXPRESS-DELIVERY/default.aspx
Fire & Flower strategically positioned to expand its geographical footprint through the industry's first full cannabis consumer technology platform
TORONTO, Jan. 25, 2022 /CNW/ - Fire & Flower Holdings Corp. ("Fire & Flower" or the "Company") (TSX: FAF) (OTCQX: FFLWF), a leading, technology-powered, cannabis retailer, today announced the Company has completed the acquisition of Pineapple Express Delivery Inc. ("Pineapple Express Delivery" or "PED"), a leading logistics technology company offering compliant and secure delivery services for controlled substances and regulated products, including transportation and delivery of medical and recreational products in Ontario, Manitoba and Saskatchewan, and liquor products in Saskatchewan. The acquisition of Pineapple Express Delivery provides Fire & Flower with the final component to execute upon its strategy of offering a full consumer technology platform to the cannabis industry.
PED is widely recognized throughout the cannabis industry as the largest player in the cannabis delivery space, completing more than 40,000 deliveries per month to recreational and medical cannabis customers across Canada. Through this strategic acquisition, Fire & Flower has completed its proprietary technology stack to deliver a seamless customer experience by combining its technology-driven retail network of over 100 stores across North America with this newly acquired, best-in-class cannabis fulfillment and delivery service.
Trevor Fencott, Chief Executive Officer of Fire & Flower, stated, "The acquisition of Pineapple Express Delivery marks the final step in building, what we believe to be, the cannabis industry's first end-to-end consumer technology experience. With a full omni-channel retail strategy, a data-driven analytics platform, and now same-day, last-mile delivery capabilities, we've developed an asset-light technology stack that can support the entire cannabis retail ecosystem, from initial customer acquisition, through product discovery, ultimately ending at the customers' front door."
"Our Hifyre™ technology powered retail network has quickly driven greater high-margin revenue streams for Fire & Flower and the inclusion of Canada's largest cannabis delivery and logistics services strategically supports our business model as we enter new markets utilizing our high-margin, scalable technology infrastructure. We look forward to rolling out our enhanced cannabis technology platform throughout Canada and eventually the U.S. with our strategic partner, Alimentation Couche-Tard, to demonstrate the unparalleled value of this model," concluded Fencott.
"It is exciting to see the completion of this acquisition and entering the next phase of the Pineapple Express Delivery story. By joining Hifyre and Fire & Flower, PED will continue to build one of the largest cannabis delivery platforms in Canada and the U.S.," shared Randy Rolph, Founder of PED. "Pineapple Express Delivery will complement the Fire & Flower business model and Hifyre will continue to add meaningful value to the business through its industry-leading technology platform and analytics. We believe this is a winning combination as our companies share an unwavering focus on supporting and empowering businesses, consumers and our communities. Together we will continue to grow and innovate, and this acquisition of Pineapple Express Delivery is a natural and timely fit given our broader expansion strategy."
As consideration for the purchase of Pineapple Express Delivery, Fire & Flower has assumed and repaid approximately $5.15 million in debt owed by Pineapple Express Delivery and issued a total of 1,153,142 common shares of Fire & Flower ("Common Shares"), of which a total of 313,708 have been released and the remainder have been placed into escrow pending completion of customary working capital adjustments and subject to achievement of certain performance-based milestones in the fiscal 2022 year. Haywood Securities Inc. acted as exclusive financial advisor to Pineapple Express Delivery.
To learn more about Pineapple Express Delivery, visit https://pineappleexpressdelivery.com/.
About Fire & Flower
Fire & Flower is a leading, technology-powered, adult-use cannabis retailer with more than 100 corporate-owned stores in its network. The Company leverages its wholly-owned technology development subsidiary, Hifyre, to continually advance its proprietary retail operations model while also providing additional independent high-margin revenue streams. Fire & Flower guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the Hifyre digital retail and analytics platform empowers retailers to optimize their connections with consumers. The Company's leadership team combines extensive experience in the technology, cannabis and retail industries.
Through the strategic investment of Alimentation Couche-Tard Inc. (owner of Circle K convenience stores), the Company has set its sights on global expansion as new cannabis markets emerge and is poised to expand into the United States when permitted through its strategic licensing agreement with Fire & Flower U.S. Holdings upon the occurrence of certain changes to the cannabis regulatory regime.
Fire & Flower is a multi-banner cannabis retail operator that owns and operates the Fire & Flower, Friendly Stranger, Happy Dayz and Hotbox brands. Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc. and Friendly Stranger Holdings Corp., licensed cannabis retailers that own and operate cannabis retail stores in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and the Yukon territory.
To learn more about Fire & Flower, visit www.fireandflower.com.
About Pineapple Express Delivery Inc.
The Pineapple Express Delivery management team has over 10 years of experience offering same-day 60-minute delivery services in multiple industries across Canada with a record breaking 40,000 deliveries per month. Pineapple Express Delivery offers a personalized experience for its customers and has established in-depth security and delivery protocols to facilitate same-day delivery of medical and recreational cannabis across the country. Pineapple Express Delivery has been providing a same day delivery option to the legal cannabis industry from October 17, 2018 and has provincial offices set up across Canada. Pineapple Express Delivery is a subsidiary of World-Class Extractions Inc. (CSE: PUMP) (FRA: WCF) (OTCQB: WCEXF). For more information please visit https://pineappleexpressdelivery.com/.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions.
Forward-looking statements are based on the opinions and estimates of management of Fire & Flower at the date the statements are made based on information then available to the Fire & Flower. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Fire & Flower, which may cause Fire & Flower's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include: regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the impact of the COVID-19 pandemic; the ability of the Company to successfully achieve its business objectives and political and social uncertainties.
No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated April 30, 2021 and the heading "Risks and Uncertainties" in the management discussion and analysis for the quarter ended October 30, 2021 filed on its issuer profile on SEDAR at www.sedar.com . The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
SOURCE Fire & Flower Holdings Corp.
Trulieve Celebrates Completion of Statewide Retail Rebrand in Pennsylvania
January 25, 2022 at 7:40 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-celebrates-completion-statewide-retail-rebrand
Trulieve-affiliated dispensaries across the state will host event activations on Saturday, January 29
TALLAHASSEE, Fla., Jan. 25, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, is hosting a statewide grand re-branding celebration spanning all Trulieve-affiliated Pennsylvania retail locations on Saturday, Jan. 29. Trulieve invites registered medical marijuana patients and caregivers to join the celebration at each of its affiliated medical marijuana dispensaries across the state.
While all locations will be a part of the celebration, the Company will host its marquee event and ribbon cutting at Chamounix Ventures, LLC d/b/a Trulieve (300 Packer Ave, Philadelphia, PA). There will be two additional ribbon cuttings with similar re-branding event activations at SMPB Retail, LLC d/b/a Trulieve (3225 N 5th Street, Reading, PA ) and Keystone Relief Centers d/b/a Trulieve (200 Adios Dr. Suite 20, Washington, PA).
"As a cornerstone market for Trulieve, we are proud to serve Pennsylvania's patient population with an unrivaled selection of the highest-quality medical marijuana products at all of our affiliated dispensaries across the state," said Kim Rivers, Chief Executive Officer of Trulieve. "Over the last year, our retail team's unwavering commitment to patients has created a growing community of "Trulievers" in Pennsylvania, where we've rebranded each of our affiliated dispensaries under the Trulieve banner. We look forward to celebrating with our extended Trulieve community and welcoming patients in our affiliated dispensaries for years to come."
Trulieve's statewide celebration commemorates the rebranding of its affiliated retail dispensaries, located in Camp Hill, Cranberry Township, Devon, Harrisburg, Johnstown, King of Prussia, Pittsburgh, Philadelphia, Reading, Scranton, Washington, Whitehall, York and Zelienople.
To find a location or to learn how to become a registered patient, visit Trulieve.com, follow us on Instagram at trulieve_pa or connect with Trulieve PA on Facebook.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Investor Contact
Christine Hersey, Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
MATTIO Communications
Trulieve@Mattio.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-celebrates-completion-of-statewide-retail-rebrand-in-pennsylvania-301467418.html
SOURCE Trulieve Cannabis Corp.
Tilray Expands Medical Cannabis Product Offering in Australia
January 25, 2022 at 7:00 AM EST
https://ir.tilray.com/news-releases/news-release-details/tilray-expands-medical-cannabis-product-offering-australia
New Tilray Branded and GMP-Certified 15g Medical Cannabis Whole Flower Now Available for Patients Under Australia’s TGA Special Access and Authorized Prescriber Scheme
Company Launches Online Medical Cannabis Education Platform for Healthcare Professions in Australia and New Zealand
NEW YORK and SYDNEY, Australia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its medical cannabis product offering in Australia and a new medical cannabis e-learning platform for healthcare providers.
Denise Faltischek, Head of International and Chief Strategy Officer, said, “Tilray is transforming the industry globally with our highly scalable footprint and portfolio of diverse cannabis products. As medical cannabis demand increases worldwide, we remain committed to providing healthcare professionals and patients with safe and reliable access to the highest-quality medical cannabis products.” Ms. Faltischek continued, “After listening to patient feedback and leveraging learnings from our operations in Germany, we are excited to be introducing new products in Australia that meet consumer needs.”
Tilray's product offering in Australia approved under the Therapeutic Goods Administration (TGA) Special Access and Authorized Prescriber Scheme is centered around its whole flower options ranging from balanced 1:1 whole flower (THC 10 CBD 10), including mid-range (17), and high THC (25) varieties of 15g bag GMP-Certified medical cannabis whole flower.
George Polimenakos, General Manager, Tilray Australia, and New Zealand, said, "We are committed to providing reliable access to patients in need with pharmaceutical-grade medical cannabis products and are pleased to be expanding our medical cannabis offerings in Australia." Mr. Polimenakos continued, “On a related note, cannabis education is paramount to everything we do and are therefore excited to offer healthcare professionals with the tools they need to learn about cannabis through our new e-learning platform.”
Tilray’s new medical cannabis educational platform for healthcare professionals is built on the importance of understanding the benefits derived from medical cannabis use. To date, Tilray has successfully introduced multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of health care practitioners in 2021.
In addition to supplying hospitals and pharmacies, Tilray is a proud partner with several leading research institutions, including the Murdoch Children's Research Institute in Australia, studying the effectiveness of Tilray medical cannabis as a treatment for pediatric patients with Intellectual Disabilities suffering from Severe Behavioral Problems; a clinical trial in partnership with The Government of New South Wales and University of Sydney Chris O'Brien Lifehouse to develop a novel treatment for chemotherapy-induced nausea, and a study led by the University of Sydney examining the effects of driving under the influence of cannabis.
Today, Tilray is one of the leading providers of GMP-certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers across the globe.
For more information about Tilray medical cannabis in Australia and New Zealand, visit: https://www.tilray.com.au/
For more information about the Tilray medicinal cannabis workshops in Australia, visit: https://tilray.medihuanna.com/
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: ; the Company’s ability to commercialize new and innovative products worldwide, including in Australia; expectations regarding worldwide medical cannabis demand; and expectations regarding regulatory approval and commercialization of medical cannabis products. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Contacts:
Tilray Global:
Berrin Noorata
news@tilray.com
Investors
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com
The Valens Company Launches Two New Brands in Value and Premium Markets
https://www.newswire.ca/news-releases/the-valens-company-launches-two-new-brands-in-value-and-premium-markets-843132787.html
The Valens Company Inc.
Jan 25, 2022, 07:00 ET
Value brand 'Versus' and ultra-premium brand 'Contraband' are part of a multi-step strategy to better meet the needs of target consumers and grow the Valens adult recreational market portfolio
KELOWNA, BC, Jan. 25, 2022 /CNW/ - The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS)) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to announce the launch of Versus, an evolution of its Verse value brand. The launch involves the introduction of two net new Versus product lines this week, plus a rebranding of the full Verse portfolio this spring, for a total of approximately 20 SKUs across product categories. Consumers interested in finding out more about Versus and its line of products can go here. Valens is also launching its new ultra-premium brand, Contraband, this week with two sizes of CNDYLND flower, consumers interested in finding out more about Contraband can go here.
This repositioning and expansion mark the beginning of a strategic, multi-step plan to grow the Valens brand portfolio into one of the top performers in the adult recreational market. The Versus launch follows Valens' acquisition of Verse Cannabis in September 2021, which, with its acquisition of Citizen Stash, propelled Valens into a top-tier market share position in Canada, while remaining a partner-of-choice for third-party custom manufacturing partners.
"The acquisition of Verse was critical because it got us a wide base of listings in seven provinces, across multiple categories, in the very important value-priced segment," said Tyler Robson, Chief Executive Officer and Chair of The Valens Company. "Relaunched as Versus, it will be the challenger that isn't afraid to go toe-to-toe with every value brand competitor, and we're confident that it will come out on top in terms of product quality and consumer satisfaction."
"Valens is uniquely positioned to succeed with Versus because we're an innovation powerhouse," Robson continued. "To thrive in value, you must to be super agile and get new products and formats out very quickly, and that's what we're all about." The new brand addresses feedback from consumers and budtenders, and uses simplified, bold packaging and logos that convey the 'fighting spirit' of Versus.
Cannabis and urban music, fashion and art has always been closely intertwined. Contraband was born out of that existing connection, which has fueled so many great works of cultural creativity. With our founder a huge supporter of that culture, we also wanted to also pay homage to the long legacy left by the original cannabis cultivators and disruptors who created the conditions that led to today's legal market. That is the origin of Contraband – a product that was once illegal is now legal but still a catalyst for great music, art, and fashion. As we develop the brand, we plan to contribute to the development of those areas of culture in a legal and responsible way. By leveraging Citizen Stash's catalogue of premium genetics Valens will add a new line of ultra-premium products, expanding its reach to a new, more discerning consumer in this fast growing, high value segment. CNDYLND flower in two sizes (3.5g and 14g) will be the first launches, beginning in Ontario, followed later this year by pre-rolls, concentrates, and vapes.
"Winning in the value price point across multiple categories will give us a solid foundation," said Robson. "From there, Contraband is part of our strategy to build an ultra-premium brand offering, and ultimately create one of the most comprehensive and effective portfolios in the marketplace".
At Valens, it's Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company's high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada's only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management's expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as "plans", "expects", "scheduled", "trends", "forecasts", "future", "indications", "potential", "estimates", "predicts", "anticipate", "to establish", "believe", "intend", "ability to", or statements that certain actions, events or results "may", "should", "could", "would", "might", "will", or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company's latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company's website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
SOURCE The Valens Company Inc.
For further information: Jeff Fallows, The Valens Company, Investor Relations, ir@thevalenscompany.com, 1.647.956.8254; KCSA Strategic Communications, Phil Carlson, VLNS@kcsa.com, 1.212.896.1233; Media, KCSA Strategic Communications, Anne Donohoe, adonohoe@kcsa.com, 1 212.896.1265
Do you read the S1 as a formality registration for previous dilution for those shareholders who received the shares as payment to now be able to sell their shares just in case they want to?
The Street isn’t going to move before legalization gets a fair vote.
Agreed, though it helps to keep increasing the top and bottom lines.
Unilever is unlikely to acquire GlaxoSmithKline’s consumer unit
Unilever update, 19 January 2022
Published: 18/01/2022
https://www.unilever.com/news/press-and-media/press-releases/2022/unilever-update-19-january-2022/
London, 19 January 2022. We note the recently shared financial assumptions from the current owners of GSK Consumer Healthcare and have determined that it does not change our view on fundamental value.
Accordingly, we will not increase our offer above £50bn.
Unilever is committed to maintaining strict financial discipline to ensure that acquisitions create value for our shareholders. Unilever also reiterates its commitment to continuing to improve the performance of its existing portfolio through its ongoing focus on operational excellence, its upcoming reorganization and by rotating the portfolio to higher growth categories.
We look forward to updating on our performance for Q4, and the full year, on February 10th and continued engagement with shareholders.
The Worst Mistake Trulieve's Investors Can Make Right Now
If the marijuana industry sell-off is pushing you to give up on its stock, hang on.
By: Sushree Mohanty
Jan 20, 2022 at 5:45AM
Key Points
* Analysts see an upside of 157% for this pot stock in the next 12 months.
* Recreational-cannabis legalization in Florida could be a cherry on top.
* Expanding into new markets will give a boost to revenue and profits.
Despite the cannabis industry sell-off, now is not the time to get disheartened with marijuana stocks. The industry is just heating up and more states could legalize cannabis this year.
Although prospects of federal legalization aren't looking favorable now, most of the domestic companies are positioned to benefit investors long-term if and when legalization happens.
Florida-based Trulieve Cannabis (OTC:TCNNF) is one such cannabis grower that has shown outstanding growth in the last couple of years, even with a limited legal market. The worst mistake Trulieve investors can make right now is to sell this stock due to the industry's downtrend. Here are the reasons why.
Focusing on strengthening Florida roots paid off
While many pot companies struggled to achieve profitability, Trulieve started making profits a while ago -- thanks to its focus on strengthening its roots in its home market of Florida. Although initially, investors were worried Trulieve's sole focus on the medical-cannabis market would make it a weaker player, the company proved that wrong.
What started as a small medical-cannabis company is now a dominant player in the Sunshine State, with 112 dispensaries. This dominance will act as a competitive moat if recreational cannabis is legalized in Florida (efforts are ongoing in the state).
This smart strategy has allowed the company to make profits for 15 consecutive quarters. Its recent third-quarter recorded net profits of $19 million, a 7% year-over-year growth, and a 64% year-over-year revenue growth of $224 million.
Now is the time to aggressively expand
After strengthening its roots, the company is slowly focusing on stretching into other key cannabis markets. The company also operates dispensaries in California, Connecticut, Massachusetts, Pennsylvania, West Virginia, Arizona, and Maryland. Its acquisition of Harvest Health (completed in October 2021) gave it access to Arizona, Pennsylvania, and Maryland. The company stated in the Q3 earnings call that post-Harvest acquisition, they saw a "35% increase in the revenue run rate."
Excluding revenue from the acquisition, Trulieve expects full-year revenue to come in the range of $815 million to $850 million and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to be in the range of $355 million to $375 million. Thus, investors can expect revenue to cross $1 billion, including the Harvest Health acquisition.
Recently, Trulieve acquired PurpleMed Healing Center in Tucson, Arizona, which marked its 17th dispensary in the state for both its medical- and recreational-cannabis patients. Arizona is an upcoming market that's recently legalized recreational marijuana. Having a stronghold in the state will be advantageous when adult-use sales ramp up.
The company has also realized the importance of the burgeoning U.S. recreational-cannabis market, which is expected to grow to a $42 billion market by 2026. Therefore, it launched a few high-margin cannabis derivatives (including gels, chocolates, cookies, and brownies) in its third quarter of 2020 for its medical-cannabis customers in Florida.
Recently, Trulieve also launched a variety of tetrahydrocannabinol (THC)-infused edibles -- chocolates, in particular, along with its partnership with the award-winning cannabis-infused chocolate company, Bhang. In November, it launched TruTonic, Florida's first edible drink mix, where each unit contains 10 pre-packaged 5mg THC doses.
These products will give a boost to Trulieve's recreational segment. The company has some strong competition in the space. Its peers Green Thumb Industries and Curaleaf Holdings, which operate 73 and 128 dispensaries, respectively, nationwide, have already expanded in the recreational segment.
Trulieve could also consider expanding to New York and New Jersey, upcoming cannabis markets where both medical and recreational pot is legal. The company is well-poised financially to fuel its expansion.
This is why it's the right time not to give up on this stock
Along with growing revenues and profits, Trulieve made sure to keep its balance sheet stable, which will boost its expansion plans this year. It ended the third quarter with a cash balance of $213.6 million and no debt. Management stated in the earnings call that the company "retired $270 million of high cost and short-term Harvest debt and $18 million of Trulieve notes payable."
Trulieve's management believes the company's strong financial position will allow them to capitalize on expansion opportunities and go deeper in the states in which they operate. For now, Trulieve has a total of 159 dispensaries in 11 U.S. states (which also includes some rebranding of Harvest Health stores).
With Trulieve's stock jumping 120% in the past two years, the company has the potential to boost its stock price even more. For investors who have the patience and are looking for an excellent growth stock, Trulieve is a stock to keep your eye on. Trulieve's shares are trading almost 50% below their 52-week high. Analysts expect an upside of 157% for this pot stock in the next 12 months, which I believe is possible.
Boost Your 2022 Wellness Routine With Manitoba Harvest
January 20, 2022 at 8:00 AM EST
https://ir.tilray.com/news-releases/news-release-details/boost-your-2022-wellness-routine-manitoba-harvest
Manitoba Harvest Shares NEW Delicious Recipes Compatible with Vegan, Keto, Paleo, and Gluten-Free Diets
MINNEAPOLIS and WINNIPEG, Manitoba, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Manitoba Harvest, a leading hemp food manufacturer and pioneer in the natural foods industry and a wholly owned subsidiary of Tilray Brands, Inc., wants you to discover the benefits of Hemp Hearts to support your 2022 holistic wellness routine. There is no doubt that the past two years have been stressful, leaving many people burned out and exhausted. Manitoba Harvest invites you to boost your 2022 wellness plan with Hemp Hearts!
How Hemp Hearts Boost Your Wellness Routine
Each serving of Hemp Hearts delivers 10g of plant protein, 12g of Omegas 3 & 6, all nine essential amino acids1, and is rich in nutrients like magnesium and zinc, both of which are factors in energy metabolism. These small but mighty seeds are packed with essential benefits that serve as extra fuel for our bodies while we tackle the year ahead.
Rich in nutrients and highly versatile, hemp is one of the best superfoods out there. Adding Manitoba Harvest Organic Hemp Hearts to your routine is one simple new year’s resolution you can add to your list. They’re compatible with vegan, keto, paleo, and gluten-free diets, so you can get creative with your meals and feel inspired to elevate your current routine.
If you love refreshing smoothies, blend the hemp hearts in for an extra nutritional boost. Top off your yogurt, oatmeal, or toss them in a salad. If you’ve just finished a workout, or you’re simply on the go, try an avocado toast sprinkled with hemp hearts for a quick breakfast, or even create your own hemp salad dressing. They’re perfect to experiment with because of the unique texture and subtle flavor while powerfully serving as the simplest health hack you never knew you needed.
Check out these incredible recipes as you discover more about hemp!
Sunshine Smoothie Bowl
Maple & Cinnamon Hemp Oatmeal
Keto Mediterranean Greek Salad
About Manitoba Harvest
Manitoba Harvest is a pioneer and leader in branded, hemp-based foods and is recognized as a Certified B Corporation and the first Canadian food company to attain a Carbonzero Certification.
Taking the seed-to-shelf approach since 1998, Manitoba Harvest is committed to quality, sustainability, and consumer wellness. They are a wholly-owned subsidiary of Tilray Brands, Inc. (NASDAQ I TSX: TLRY), dedicated to hemp education and consumer wellness.
With an extensive product portfolio of Hemp Hearts (shelled hemp seed), Hemp Protein, Hemp Protein Blends, Hemp Wellness Bars, Hemp Granola, and Hemp Oil, their products are sold globally in approximately 17,000 retail stores across the United States and Canada. From Manitoba Harvest themselves: “Whether you are buying our organic hemp hearts or our natural hemp hearts, you know you’re getting the best possible hemp product – grown by farmers who really care about their crops and monitored by Manitoba Harvest agronomists who are experts in the space.”
For U.S., visit www.manitobaharvest.com to learn more about the brand story and purchase products.
For Canada, visit www.manitobaharvest.ca to learn more about the brand story and purchase products.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, holistic health benefits of Manitoba Harvest Hemp Hearts. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to Tilray or that Tilray deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and Tilray does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Press Contact:
Caitlyn Pulitzer
cpulitzer@manitobaharvest.com
612-210-4988
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f0a39e49-f234-45b0-967c-54f9616e0f6c
_______________
1 Hemp essential amino acid profile per 30g serving contains Histidine (0.20g), Isoleucine (0.41g), Leucine (0.67g), Lysine (0.37g), Methionine (0.27g), Phenylalanine (0.50g), Threonine (0.40g), Tryptophan (0.09g), and Valine (0.48g).
THE VALENS COMPANY TO PARTICIPATE IN KCSA CANNABIS VIRTUAL INVESTOR CONFERENCE
KELOWNA, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) — The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the “Company” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to announce that Everett Knight, Executive Vice President, Corporate Development & Capital Markets, will participate in the KCSA Cannabis Virtual Investor Conference on January 20, 2022.
DATE: January 20, 2022
TIME: 1:00 PM ET
REGISTRATION LINK: https://bit.ly/3JUNHjN
This will be a live, interactive online event where investors are invited to ask the Company questions, in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event has concluded.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com
At Valens, it’s Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
ABOUT THE VALENS COMPANY
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company’s investor deck can be found specifically at https://thevalenscompany.com/investors/.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Jeff Fallows
The Valens Company
Investor Relations
ir@thevalenscompany.com
1 647.956.8254
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VLNS@kcsa.com
1 212.896.1233 / 1 212.896.1203
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265
NOTICE REGARDING FORWARD LOOKING STATEMENTS
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.
The risks and uncertainties that may affect forward-looking statements include, among others, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
Curaleaf Opens Two New Pennsylvania Dispensaries
New locations in Greensburg and Wayne expand the Company's retail presence to 14 locations in one of the country's largest medical markets
WAKEFIELD, Mass., Jan. 20, 2022 /PRNewswire/ --Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced plans to open two new dispensaries in Pennsylvania. Curaleaf's latest locations in Greensburg and Wayne will increase the Company's retail footprint to 14 dispensaries statewide and 125 across the country. Two additional locations, Curaleaf Erie (7891 Peach St.) and Curaleaf State College (1248 S Atherton St.), are expected to open by the end of February, pending regulatory approval.
Curaleaf Greensburg, located at 5133 US-30, is the first of the dispensaries to hold a Grand Opening today, January 20. Curaleaf Wayne, located at 707 Lancaster Ave., has already undergone a soft opening and will celebrate its Grand Opening on Thursday, January 27. The Company's newest retail locations are dedicated to being a leading resource in research-based patient education and advocacy. Patients will have access to a selection of Curaleaf's top-selling vaporizer and whole flower products, including Select Elite, Select Elite Live, Grassroots Full-Spectrum RSOs, RSO capsules, prepackaged flower, distillate cartridges, strain-specific vape cartridges, as well as cured and live concentrates.
Since becoming a Clinical Registrant recognized by the Commonwealth's Department of Health in 2020, Curaleaf's Pennsylvania subsidiaries have supported research initiatives examining the potential benefits of cannabis by providing medical marijuana and guidance to patients. Curaleaf's first-in-the-nation research program builds upon the Company's ongoing efforts to provide clinically supported resources to Pennsylvania's over 681,000 registered patients.
"Curaleaf is proud to broaden its scope of patient care and provide premium medical marijuana products to our Greensburg and Wayne medical communities," said Chief Executive Officer Joe Bayern. "Our latest retail expansion allows us to further support patients in the state of Pennsylvania and work with esteemed scientists on essential medical marijuana studies that will empower both physicians and patients to make confident and informed decisions."
In addition to Curaleaf's latest two locations, the Company also serves patients through its Curaleaf dispensaries in Altoona, Bradford, Brookville, City Avenue, DuBois, Gettysburg, Harrisburg, Horsham, King of Prussia, Lebanon, Morton and Philadelphia. In the coming weeks, Curaleaf will offer grand opening discounts to veterans, seniors and first-time patients at all Pennsylvania locations. For more information on store openings, along with product offerings and hours of operation, please visit https://curaleaf.com/locations#pennsylvania.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 23 states with 125 dispensaries, 25 cultivation sites, and employs over 5,200 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Forward Looking Statements
This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or, "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning the opening of four new dispensaries in the state of Pennsylvania. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed April 28, 2021, which is available under the Company's SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
Carlos Madrazo, SVP Head of IR & Capital Market
IR@curaleaf.com
MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, VP Corporate Communications
media@curaleaf.com
SOURCE Curaleaf Holdings, Inc.
More detailed reasons--->>>Fire & Flower Marijuana Retailer Prepares For NASDAQ Listing, Files 40-F With SEC
by Nina Zdinjak
January 19, 2022 12:41 pm
https://www.benzinga.com/markets/cannabis/22/01/25112214/fire-flower-marijuana-retailer-prepares-for-nasdaq-listing-files-40-f-with-sec
Fire & Flower Marijuana Retailer Prepares For NASDAQ Listing, Files 40-F With SEC
FFLWF announced the filing of its Form 40-F Registration Statement with the US Securities and Exchange Commission (SEC) in preparation for the company to list its shares on the Nasdaq Stock Market LLC.
"Fire & Flower's anticipated listing on the Nasdaq is strategically aligned with our expanded digital e-commerce offering and its planned entry into the U.S. cannabis market," Trevor Fencott, CEO of Fire & Flower said on Wednesday. "We have quickly demonstrated the success of our technology-driven retail model in Canada's cannabis market, becoming the first company to build a true cannabis consumer technology platform. Listing on the Nasdaq will allow us to expand our shareholder base and drive increased shareholder value as we continue to leverage our unique technology-driven business model to enter new targeted markets across North America. We are excited to share our vision for 'smart' cannabis retail to a broader audience of investors."
Listing of Fire & Flower’s common shares on Nasdaq remains subject to the approval of the Nasdaq and satisfaction of all applicable listing and regulatory requirements, including the effectiveness of Form 40-F. Following receipt of all required approvals, the company will issue a press release announcing its first trading date on Nasdaq.
Fire & Flower's common shares will continue to trade on the OTCQX under the ticker FFLWF until the commencement of trading on the Nasdaq. Its common shares will continue to trade on the Toronto Stock Exchange under the ticker symbol "FAF" following the completion of the proposed Nasdaq listing.
My gut reaction is that Blair Wellness didn't meet all of the deal's terms because they were probably trying to hide something that would have valued the business for less, or their accounting showed irregularities.
The transparency wasn't there to justify the price or worth renegotiating.
It's a mature move by CRESCO to walk away.
GREEN ROADS LAUNCHES ‘OWN THE DAY’ BRAND CAMPAIGN
https://thevalenscompany.com/press-releases/green-roads-launches-own-the-day-brand-campaign/
KELOWNA, BC, Jan. 19, 2022 /PRNewswire/ – Green Roads, a subsidiary of The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS)) (the “Company” “The Valens Company” or “Valens”), announces the launch of its first-ever brand campaign “Own the Day”. The campaign celebrates Green Roads’ products and their ability to help consumers with common health and wellness challenges such as stress, sleep, muscle and joint pain, relaxation, and focus. For any consumers interested in finding out more about Green Roads products they can click here.
Green Roads also relaunched its DTC e-commerce experience to carry the Own the Day messaging and prominently feature the solutions and personas featured in the campaign.
“We believe that health and wellness is a Personal journey and that great days are built by small moments, whether it’s relaxing after a frantic day, staying focused on things that matter or liberating yourself with restful sleep,” said Tyler Robson, Chief Executive Officer and Chair of The Valens Company. “With this campaign, we want to position Green Roads as a trusted partner with a portfolio of products aimed at helping consumers achieve their personal health and wellness objectives.”
“Own the Day” was created in partnership with Known, the agency of record for media and creative for Green Roads. This new campaign leverages Known’s Skeptic™ Operating System, which uses machine learning and AI to deploy and optimize thousands of creative permutations in real time. Other Known clients include Netflix, Google, Beyond Meat, BeautyCounter, Just Egg and more.
At Valens, it’s Personal.
About Green Roads
Green Roads is an award-winning company that produces high-quality wellness products using hemp-derived CBD and other beneficial cannabinoids. Through premium CBD oils, edibles, soft gels, capsules, topicals, coffee, and more, Green Roads is on a mission to help every person find the healthiest version of themselves through the power of plants. Green Roads is unique in that it is one of a very small number of CBD brands that produce their own products in their own cGMP facility. Green Roads products are sold in over 7,000 retail locations and online at greenroads.com. Headquartered in Deerfield Beach, FL, its products are available across the U.S., in health food stores, doctors’ offices, yoga studios, smoke shops, vitamin shops, juice and smoothie bars, wellness centers, and many other retail locations.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
ABOUT THE VALENS COMPANY
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company’s investor deck can be found specifically at https://thevalenscompany.com/investors/.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Jeff Fallows
The Valens Company
Investor Relations
ir@thevalenscompany.com
1 647.956.8254
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VLNS@kcsa.com
1 212.896.1233 / 1 212.896.1203
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265
NOTICE REGARDING FORWARD LOOKING STATEMENTS
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.
The risks and uncertainties that may affect forward-looking statements include, among others, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
Sure would like the dividend to rise in 2022 by a more significant amount than the 4¢ per year done over the last 2 years.
The 20¢ jump in 2019 is more like it.
IMO Valens is doing all of the right things. They are focused on expanding avenues to market.
They aren't laser focused on posting positive earnings yet. As soon as they accomplish that, the PPS will respond.
This article partly points out why I reason that after a great run this year, that I see the year-end PPS near $110
And then if more debt is paid down during 2022 and there is a December dividend increase announcement for 2023, the PPS should move up again in 2023.
Don't forget that they are closing 90 stores.
I think the Street caught up with my love affair with CVS.
https://seekingalpha.com/article/4480411-cvs-dividend-stock-watch-after-dividend-increase?messageid=2800&utm_campaign=4480411&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+Article+Smart ;
Is CVS A Dividend Stock To Watch After The Dividend Increase?
Jan. 19, 2022 4:35 PM ETCVS Health Corporation (CVS)1 Comment3 Likes
Chuck Walston profile picture
Chuck Walston
Marketplace
Summary
After a hiatus designed to reduce debt following the Aetna acquisition, CVS recently raised its dividend payout for the first time since 2017.
The firm’s three segments generate synergies, while the PBM and Aetna provide shallow but enduring moats.
Investors fear competition from Amazon.
Looking for a helping hand in the market? Members of High Dividend Opportunities get exclusive ideas and guidance to navigate any climate. Learn More »
Las Vegas Strip - CVS
LPETTET/iStock Unreleased via Getty Images
In Q3, CVS Health Corporation (NYSE:CVS) posted its second straight quarter of double-digit, year-over-year revenue growth. The latest earnings also marked the 14th consecutive quarter that CVS exceeded analysts' revenue expectations. Then early this week, the company raised its FY21 diluted EPS guidance and also reaffirmed FY22 adjusted EPS guidance of $8.10 to $8.30.
Those results, combined with the first increase in the dividend payout since 2016, helped to push the share price higher. CVS now trades near 52-week highs. The strong quarterly reports also reflect the integration of Aetna following the acquisition of that company in late 2018.
While many characterize CVS as a retailer, in fact, the company only derives about a third of its profits from the retail segment. Furthermore, CVS can rightfully claim that the retail business, the pharmacy benefit management (PBM) segment, and Aetna are all leaders in their respective fields.
Of course, the company still faces fierce competition, and some investors have been spooked by Amazon's entrance into the pharmacy business.
The Transformation Of CVS
In 2007, CVS acquired Caremark RX, a PBM. Then in late 2018, the company completed its acquisition of Aetna. With those deals, CVS was transformed from a retail pharmacy into a health care provider delivering an integrated health care experience. Furthermore, each segment provides operational efficiencies for the others, creating a competitive advantage over most rivals.
However, the Aetna deal cost CVS $69 billion. To buttress the balance sheet, management moved to freeze the dividend and halt stock buybacks. This led to a period of malaise in the share price. The stock dropped immediately after the deal and did not recover to pre-acquisition levels until April of this year.
The debt burden from adding Aetna pushed the company's leverage ratio to 4.7x. In turn, the major rating agencies lowered the company's debt scores. First, S&P reduced the company's debt rating from BBB+ to BBB with a stable outlook. Then Moody's followed suit, lowering its rating to Baa2 from Baa1 with a negative outlook
Since that time, management has worked diligently to pay down debt. Long term debt has been reduced by $21 billion, and the company is well along its way to reaching a goal of a low 3x leverage ratio in 2022.
Despite the added debt and the associated measures taken to restore the firm's balance sheet, the Aetna acquisition has paid off. The charts below provide evidence of the growth in revenue and EPS following the consummation of the deal.
CVS annual revenue
Macrotrends
Source: Metrics from Macrotrends & Q3 Earnings Call / Chart by author
CVS Annual EPS
Macrotrends
Source: Metrics from Macrotrends & Q3 Earnings Call / Chart by author
With 24 million members, Aetna is one of the largest insurers in the U.S. In metropolitan areas in which it is a leading provider, Aetna has a scale advantage over smaller rivals. This allows the company to offer lower costs and/or increased benefits to members. With that advantage, employers and providers are attracted to Aetna's offerings. In turn, this begets a virtuous cycle and an enduring moat.
CVS has an additional asset that strengthens its moat. The PBM operated by the company is one of the top three in the industry, along with UnitedHealth (UNH) and Cigna (CI). Combined they control nearly 80% of U.S. prescription volumes on an adjusted basis.
CVS' PBM processes approximately 2 billion, or roughly one third, of the adjusted prescriptions annually in the U.S. The scale of the PBM provides the negotiating leverage to gain discounts from drug manufacturers and pharmacies. In turn, this helps to strengthen Aetna's position as an insurer.
Prescription drug market
Statista
Source: Statista / Chart by author
The major PBM's also exhibit low churn rates from clients, with annual retention rates well above 90%.
An Ever Present Threat
In November of 2020, Amazon (AMZN) entered the pharmacy business, offering online prescription fulfillment as well as free delivery for Prime members. As one would expect, shares of CVS and Walgreens (WBA) took a dive.
Then in the middle of last year, Business Insider reported Amazon was mulling the idea of adding pharmacies to its Whole Foods stores and opening physical stores in a "handful" of locations.
While more competition is never a positive, I've reported in previous articles that contrary to conventional wisdom, Amazon does not corner the market on drug prices. Articles from Healthline and Pharmacy Checker provide evidence that Amazon's prices are often higher than that of CVS. This should come as no surprise to those that understand the advantage a PBM offers.
It should also be noted that mail-order prescriptions represent less than 20% of all prescription drug sales. Furthermore, CVS CarePass members receive free one- or two-day delivery of prescriptions as well as access to a 24/7 CVS pharmacist hotline. CVS is also using Shipt, a delivery service provider, to provide same-day prescription delivery from 6,000 locations.
I will posit that Amazon and Walmart pose far greater threats to independent pharmacies than to the major players. Rural pharmacies are being hit particularly hard. In the sixteen years leading up to 2018, over 16% of the rural pharmacies closed.
Map of pharmacies US
Kentucky Health News
Pharmacies are struggling. We're getting calls from a lot more pharmacy owners that want to sell their stores. They've had enough.
Harry Lattanzio, President of PRS Pharmacy Services
I believe it is reasonable to assume that CVS may benefit over the long term from the failure of independent pharmacies.
CVS Valuation
CVS currently trades for $106.22 per share. The 12-month average price target of the 22 analysts rating the stock is $112.95. The price target of the three analysts that rated the stock following the last earnings report is $116.66.
The company has a 5-year PEG of 2.14x, well above its average PEG of 1.44x. The forward P/E of 17.59x is nearly 3 points higher than its 5-year average P/E.
Dissecting The Dividend, And More
The current yield is 2.07%, and the payout ratio is 26.72%.
I've noted some commentators predicting that large increases in the dividend are in store. I beg to differ, and my circumspect position is based on management's pronouncements as well as the company's recent presentations.
The CEO had this to say during JP Morgan's Annual Healthcare Conference:
First, we're investing 25% to 35% in our foundational businesses, 20% will be invested in our gradually increasing dividend with growth and dividend aligned to earnings growth.
During the last earnings call, the CFO stated the dividend would grow with EPS.
A recent presentation reinforces management's guidance.
Capital generation
JP Morgan
During the latest earnings call, management provided guidance regarding expectations of growth in the coming years.
During our Investor Day in a few weeks, we look forward to sharing with you more about our path over the coming years to deliver on this ambition and to position CVS Health to generate sustainable, low double-digit adjusted EPS growth.
I think it is likely that CVS will hit the low double-digit revenue growth goal. Assuming an annual 10% dividend payout increase, we would reach a yield on a current cost basis of roughly 3% in four years.
I should add that management approved a $10 billion share repurchase plan. With the current market cap, this would result in about a 7% reduction in the share count.
Is CVS Stock A Buy, Sell, Or Hold?
To characterize CVS as a retail company is to ignore Aetna and the PBM business, which combined generate roughly two thirds of the parent company's profits. Furthermore, the PBM and Aetna provide a narrow but stable moat, and synergies exist between each of the three segments.
Management guides for sustainable EPS growth in the low double digits by 2024, and a major negative undermining investor sentiment has been removed with the resumption of share buybacks and a dividend increase. All in all, I think it reasonable to classify CVS as a very safe investment, albeit with moderate growth prospects.
I will add that companies in the health care sector tend to perform well during periods of economic uncertainty.
Last year I published two articles on CVS, and on each occasion I rated the stock as a buy. Following the article that debuted roughly a year ago, the shares beat the S&P by close to a two to one margin. The total return for CVS after my article in July is well over 4X the S&P.
I found it easy to rate the stock as a buy on those two occasions; however, I will admit that I struggled somewhat to make a decision in this instance for two reasons: a less compelling valuation and a rather modest current yield. Otherwise, I view CVS as a sound investment.
Unless I can provide a buy rating without reservation, I prefer to err on the side of caution.
Consequently, I rate CVS as a HOLD.
This article was written by
Chuck Walston profile picture
Chuck Walston
18.35K Followers
Author of
High Dividend Opportunities
The #1 Service for Income Investors and Retirees, +9% dividend yield.
As of 12/17/2021, I am rated among the top 1.3 % of authors in terms of overall results. This is according to TipRanks, which provides a 76% success rate and an average 25.6% annual return for my articles. (I update this score on at least a quarterly basis for readers.)
My primary focus is dividend bearing stocks; however, I also invest in some high growth names to boost my total return.
I am a value / buy and hold investor. Readers should consider this when weighing my buy/hold/sell recommendations. Since I require a discount in the share valuations of my investments, my ratings are generally very conservative. My valuation requirements, combined with the high quality companies that I often highlight, mean many stocks I rate as a hold perform well over the long term.
I am a retail investor, with no formal training in investing.
I am a graduate of the U.S Army Ranger school and a former member of the 1st Ranger Battalion and The Old Guard (U.S Army Honor Guard.) I am a retired law enforcement officer. I have approximately 18 years experience as a retail investor.
Best of luck in your investments, Chuck
Show more
Follow
Disclosure: I/we have a beneficial long position in the shares of CVS, CI, UNH, WBA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: I have no formal training in investing. All articles are my personal perspective on a given prospective investment and should not be considered as investment advice. Due diligence should be exercised and readers should engage in additional research and analysis before making their own investment decision. All relevant risks are not covered in this article. Although I endeavor to provide accurate data, there is a possibility that I inadvertently relay inaccurate or outdated information. Readers should consider their own unique investment profile and consider seeking advice from an investment professional before making an investment decision.
CVS Health and Uber Health collaborate to advance health equity in communities nationwide
Wednesday, January 19, 2022
Collaboration will provide free transportation through new Health Zones initiative
https://cvshealth.com/news-and-insights/press-releases/cvs-health-and-uber-health-collaborate-to-advance-health-equity
WOONSOCKET, R.I. — CVS Health (NYSE: CVS) today announced a collaboration with Uber Health, Uber's healthcare arm, to provide critical transportation support at no cost to people who need it most when seeking access to medical care, work or educational programs.
The relationship is part of Health Zones, CVS Health's new initiative that provides concentrated local investments designed to reduce health disparities and advance health equity in high-risk communities across the country. Health Zones is an integrated approach to addressing six key social determinants of health: housing, education, access to food, labor, transportation, and health care access. The Health Zones initiative is now active in five markets nationwide: Atlanta, GA; Columbus, OH; Fresno, CA; Hartford, CT; and Phoenix, AZ with plans to expand into more cities later this year. Working with trusted national and local partners, CVS Health is addressing community health care needs, ensuring at-risk communities have access to resources and opportunities that can help them thrive.
CVS Health and Uber Health will help eliminate a critical barrier to care and overall well-being transportation which can limit a person's ability to receive medical care, to get to work or to job trainings and can ultimately lead to adverse health outcomes. Rides with Uber Health will be available to a target population living in three of the five Health Zones: Atlanta, GA; Columbus, OH; and Hartford, CT with plans to enter additional cities later this year.
"Our Health Zones initiative allows us to make a real impact on the health of communities across the country by working closely with organizations that share our commitment to addressing social determinants of health," said Eileen Howard Boone, Senior Vice President of Corporate Social Responsibility & Philanthropy and Chief Sustainability Officer, CVS Health. "With the Uber Health platform, we'll provide critical transportation to people within communities who need it most, giving them access to health care services so they can live healthier lives and to jobs and educational programs that can help them reach their full potential."
"We've long known that access to reliable transportation can help address critical gaps in care that often disproportionately affect vulnerable communities. With the past two years of the pandemic only further highlighting today's health inequities, it's more important than ever for communities to have the tools they need to bridge care gaps and achieve better patient and population health outcomes," said Caitlin Donovan, Global Head of Uber Health. "Uber Health is proud to be a part of CVS Health's new Health Zones initiative and encourages community organizations to address transportation as a key social determinant of health, while improving health outcomes in a scalable way."
For Uber Health, the relationship with CVS Health is a natural extension of its broader commitment to improving population health care management, so more people can achieve and maintain healthy lifestyles. Its HIPAA-supported solution is utilized by more than 2,000 health care organizations across the U.S.
Health Zones is part of CVS Health's overall commitment to advance health equity in America. In 2021, CVS Health invested $185 million in affordable housing nationwide and $1.3 billion over the past 20 years. Through these investments, CVS Health has been able to provide underserved communities with quality housing, economic support, and educational training opportunities based on the unique needs of the population.
CVS Health continues to help ensure equitable access to COVID-19 testing and vaccinations across the country. Approximately 40 percent of vaccines have been provided to underserved communities and more than 50 percent of CVS Health's testing sites have also supported these communities.
Learn more about CVS Health's new Health Zones initiative and the collaboration with Uber Health.
About CVS Health
CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and approximately 300,000 dedicated colleagues including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health whether that's managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system and their personal health care by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.
About Uber Health
Since 2018, Uber Health's HIPAA-supported solution has become the logistics platform of choice for healthcare organizations focused on population health management. From non-emergency medical transportation, nutritional meals to prescription delivery, Uber Health can help connect millions to the care they need. Over 2,000 healthcare organizations like ALC Solutions, Cerner, Boston Medical Center, and ModivCare trust Uber Health to provide access to stress-free transportation for those they care for. By tapping into Uber's logistics expertise, Uber Health's API is able to facilitate everything from mobility solutions to critical deliveries, streamlining population health management and supporting better patient outcomes. For more information, visit uberhealth.com.
Media contact
Eva Pereira
781-686-4200
PereiraE1@cvshealth.com
Cresco Labs Announces Termination of Blair Wellness Acquisition
January 19, 2022
https://investors.crescolabs.com/investors/press-releases/press-release-details/2022/Cresco-Labs-Announces-Termination-of-Blair-Wellness-Acquisition/default.aspx
CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the termination of the previously announced definitive agreement to acquire 100% of the outstanding equity interest in Blair Wellness, LLC (“Blair Wellness”), a Baltimore Maryland medical cannabis dispensary (the “Transaction”).
“We have terminated the purchase agreement with Blair Wellness due to the failure of certain closing conditions to be met prior to our specified termination date,” said Charlie Bachtell, Cresco Labs’ CEO & Co-founder. “We will continue to look for other avenues to expand our footprint in Maryland, and execute our strategy of going deep in meaningful, material states.”
Blair Wellness was originally expected to close during Q4 2021. There are no termination fees associated with the Transaction.
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.
Forward Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005457/en/
Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
Investors:
investors@crescolabs.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
Source: Cresco Labs
Trulieve and Connected Cannabis Expand Partnership to Florida
January 18, 2022 at 7:30 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-and-connected-cannabis-expand-partnership-florida
Connected's products will be available to Florida's medical cannabis patients exclusively at Trulieve
TALLAHASSEE, Fla., Jan. 18, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced an expanded partnership with Connected Cannabis Co. ("Connected"), a premier cannabis cultivator. Through this agreement, Trulieve will be the exclusive producer, processor and retailer of Connected branded products throughout Florida.
Connected branded products will be available later this year exclusively at Trulieve's 111 Florida dispensaries. Trulieve already partners with Connected in Arizona.
"Trulieve is excited about expanding our partnership with Connected as we continue seeking ways to benefit our patients," said Kim Rivers, CEO of Trulieve. "Connected maintains a portfolio of proprietary top-shelf strains that our customers and patients desire in other markets and we anticipate a similar response in Florida."
Connected has been building a proprietary genetics portfolio of premium strains and meticulously cultivating cannabis at scale since 2009. With more than a decade of industry experience, they are known as a leading brand in the cannabis space and a pioneer in the industry.
"We're proud to expand our successful partnership with Trulieve to bring our award-winning Connected and Alien Labs products to the East Coast," said Caleb Counts, co-founder of Connected.
Sam Ghods, CEO of Connected, added, "We value their leadership as the top operator in the state and share their commitment to providing customers with the best products possible."
As Florida's first, largest and leading medical cannabis provider, Trulieve offers Florida's largest selection of THC and CBD products in a variety of delivery methods, including edibles, smokable flower, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers statewide home delivery, convenient online ordering, and in-store pickup.
For more information, please visit www.connectedcannabisco.com and www.Trulieve.com.
About Connected Cannabis Co.
Connected Cannabis Co. has been breeding, growing and selling the best cannabis in the world since 2009 through its Connected and Alien Labs brands. Co-founded by Caleb Counts, a master grower, with the mission of providing high-quality products paired with excellent customer service, the company has created a cult-like following and some of the most celebrated strains on the market. Today, Connected operates multiple state-of-the-art grow facilities in both California and Arizona.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve
Twitter: @Trulieve
Investor Contact
Christine Hersey, Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
Connected Logo
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-and-connected-cannabis-expand-partnership-to-florida-301462647.html
SOURCE Trulieve Cannabis Corp.